BioSpace News Archive

Opiant today reports that new pre-clinical data supporting the continued development of OPNT005 as a heroin vaccine were published online in the Journal of Medicinal Chemistry.

Athenex today announced that it has been added to the NBI, which will be effective prior to market open today, Monday, December 18, 2017.

Samumed, today announced the dosing of the first degenerative disc disease patient in its Phase 1 trial of SM04690, a small molecule Wnt pathway inhibitor formulated as an intradiscal injection.

The objective of the study is to evaluate the safety and efficacy of P-BCMA-101 in patients with relapsed/refractory multiple myeloma and determine a recommended Phase 2 dose.

Catalyst Biosciences today announces that the Korean MFDS has approved a protocol amendment to omit single dose Cohort 4 and move directly to multi-dose Cohort 5 at 150 IU/kg daily, in the ongoing Phase 1/2 multi-dose study of CB 2679d/ISU304, Catalyst’s highly potent next-generation coagulation Factor IX variant in individuals with severe hemophilia B.

VBL Therapeutics announced new biomarker data supporting the direct link between lead asset VB-111’s dual mechanism of action and clinical effect on overall survival and progression-free survival in patients from the company’s Phase 2 trial of VB-111 in recurrent glioblastoma multiforme.

Topline data is expected to be released in the second quarter of 2018.

RespireRx, is pleased to announce that a paper detailing the neurobiologic safety of the ampakine CX717 has been accepted for publication by Toxicological Sciences, the Journal of the American Society of Toxicology.

The primary efficacy endpoint of the study is the change in transferrin saturation, a standard measurement of iron levels in the body and one of the two key measurements used to detect iron overload, from baseline to end of treatment.

PCI Synthesi issued its annual list of trends that will affect the emerging biotech and generic drug sectors, as well as CDMOs, CROs and CMOs in 2018.